Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis
- 235 Downloads
In adults, growth hormone deficiency (GHD) has been associated with low bone mineral density (BMD), an effect counteracted by growth hormone (GH) replacement. Whether GH is beneficial in adults with age-related bone loss and without hypopituitarism is unclear.
We conducted a systematic literature search using Medline, Embase and the Cochrane Register of Controlled Trials. We extracted and analyzed data according to the bone outcome included [bone mineral content (BMC), BMD, and bone biomarker, fracture risk]. We performed a meta-analysis when possible.
We included eight studies. Seven randomized 272 post-menopausal women, 61–69 years, to GH or control, for 6–24 months, and the eighth was an extension trial. Except for one study, all women received concurrent osteoporosis therapies. There was no significant effect of GH, as compared to control, on BMD at the lumbar spine (Weighted mean difference WMD = −0.01 [−0.04, 0.02]), total hip (WMD = 0 [−0.05, 0.06]) or femoral neck (WMD = 0 [−0.03, 0.04]). Similarly, no effect was seen on BMC. GH significantly increased the bone formation marker procollagen type-I carboxy-terminal propeptide (PICP) (WMD = 14.03 [2.68, 25.38]). GH resulted in a trend for increase in osteocalcin and in bone resorption markers. Patients who received GH had a significant decrease in fracture risk as compared to control (RR = 0.63 [0.46, 0.87]). Reported adverse events were not major, mostly related to fluid retention.
GH may not improve bone density in women with age-related bone loss but may decrease fracture risk. Larger studies of longer duration are needed to further explore these findings in both genders, and to investigate the effect of GH on bone quality.
KeywordsBone mineral density Fracture Growth hormone Meta-analysis Osteoporosis
The authors would like to thank Dr. Elie Akl for his contribution to the methodology of the meta-analysis, Ms Aida Farha for her contribution to the systematic search and all study authors who generously provided data from their individual studies and answered study-related queries. Drs Barake, Arabi, El-Hajj Fuleihan, Tritos and Klibanski participated in study design; Drs Barake, Nakhoul and El Ghandour participated in article screening; Drs Barake and Nakhoul participated in data extraction and analysis; Drs Barake and Tritos participated in manuscript writing; All co-authors had the opportunity to revise, view and approve of the latest version of the manuscript. Research reported in this publication was supported by the Fogarty International Center and Office of Dietary Supplements of the National Institutes of Health under Award Number D43 TW009118. This funding supported the Scholars in Health Research Program (SHARP), American University of Beirut, Beirut, Lebanon. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Compliance with ethical standards
Conflict of interest
Nicholas A Tritos has received institution-directed research support from Ipsen, Novo Nordisk, Novartis and Pfizer for work unrelated to this manuscript. Anne Klibanski has received research funding from Ipsen and consultancy from Chiasma. The remaining authors declare that they have no competing interests.
- 3.P.V. Carroll, E.R. Christ, B.A. Bengtsson, L. Carlsson, J.S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, P.H. Sonksen, T. Tanaka, M. Thorne, Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83(2), 382–395 (1998). https://doi.org/10.1210/jcem.83.2.4594 CrossRefPubMedGoogle Scholar
- 4.G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21(4), 520–528 (2006). https://doi.org/10.1359/jbmr.060112 CrossRefPubMedGoogle Scholar
- 7.C. Wuster, R. Abs, B.A. Bengtsson, H. Bennmarker, U. Feldt-Rasmussen, E. Hernberg-Stahl, J.P. Monson, B. Westberg, P. Wilton, K.S. Group, K.I.B.P. the; Upjohn International Metabolic, D., The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J. Bone Miner. Res. 16(2), 398–405 (2001). https://doi.org/10.1359/jbmr.2001.16.2.398 CrossRefPubMedGoogle Scholar
- 10.A. Iranmanesh, G. Lizarralde, J.D. Veldhuis, Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 73(5), 1081–1088 (1991). https://doi.org/10.1210/jcem-73-5-1081 CrossRefPubMedGoogle Scholar
- 22.COMET: initiative. www.comet-initiative.org. Accessed in January 2016
- 25.E. Krantz, P. Trimpou, K. Landin-Wilhelmsen, Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 100(9), 3251–3259 (2015). https://doi.org/10.1210/jc.2015-1757 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.J.P.T. Higgins, S. Green, Cochrane handbook for systematic reviews of interventions. version 5.1.0. The Cochrane Collaboration (2011)Google Scholar
- 30.T.B. Hansen, K. Brixen, N. Vahl, J.O. Jorgensen, J.S. Christiansen, L. Mosekilde, C. Hagen, Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 81(9), 3352–3359 (1996). https://doi.org/10.1210/jcem.81.9.8784096 PubMedGoogle Scholar
- 31.R. Marcus, Normal and abnormal bone remodeling in man. Annu. Rev. Med. 38, 129–141 (1987). https://doi.org/10.1146/annurev.me.38.020187.001021 CrossRefPubMedGoogle Scholar
- 32.P. Gillberg, H. Mallmin, M. Petren-Mallmin, S. Ljunghall, A.G. Nilsson, Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J. Clin. Endocrinol. Metab. 87(11), 4900–4906 (2002). https://doi.org/10.1210/jc.2002-020231 CrossRefPubMedGoogle Scholar
- 33.M.E. Molitch, D.R. Clemmons, S. Malozowski, G.R. Merriam, M.L. Vance, S. Endocrine, Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(6), 1587–1609 (2011). https://doi.org/10.1210/jc.2011-0179 CrossRefPubMedGoogle Scholar
- 35.D.B. Allen, P. Backeljauw, M. Bidlingmaier, B.M. Biller, M. Boguszewski, P. Burman, G. Butler, K. Chihara, J. Christiansen, S. Cianfarani, P. Clayton, D. Clemmons, P. Cohen, F. Darendeliler, C. Deal, D. Dunger, E.M. Erfurth, J.S. Fuqua, A. Grimberg, M. Haymond, C. Higham, K. Ho, A.R. Hoffman, A. Hokken-Koelega, G. Johannsson, A. Juul, J. Kopchick, P. Lee, M. Pollak, S. Radovick, L. Robison, R. Rosenfeld, R.J. Ross, L. Savendahl, P. Saenger, H. Toft Sorensen, K. Stochholm, C. Strasburger, A. Swerdlow, M. Thorner, GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur. J. Endocrinol. 174(2), P1–9 (2016). https://doi.org/10.1530/EJE-15-0873 CrossRefPubMedGoogle Scholar